Replies to post #1870 on Enanta Pharmaceuticals Inc (ENTA)

[DewDiligence]

ABBV's 2020 HCV-sales guidance lowered to $2.3B (from prior guidance of $2.5B). The new $2.3B figure is consistent with the 1Q20 HCV sales of $564M (#msg-155372271).

On today’s 1Q20 CC, ABBV said about half of the $200K guidance reduction stems from COVID-19 issues.